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This study reports the results of a questionnaire survey of female members of the British Epilepsy Association. The women
were asked about their epilepsy and its management. A questionnaire was sent to 6000 BEA women members of whom 1855
(31%) replied.
The majority of women (89%) stated they currently take older antiepileptic medications, either as monotherapy or in combin-
ation with others. Newer antiepileptic drugs were prescribed to 30% of women. The most frequently mentioned antiepileptic
drug side-effects were tiredness and forgetfulness. Seventy percent of the sample considered that the lack of energy had at least
a moderate impact on their life. Thirty-eight percent of women would have liked better seizure control whilst 32% agreed that
they would prefer to change to a medication with fewer side-effects. However, 49% were reluctant to change their medication.
Fifty-nine percent stated that they see their hospital specialist regularly whilst half the sample (49%) saw their GP regularly.
Hospital specialists on the whole, played a more active role in the management of epilepsy than GPs. Many women (68%) felt
that their GP’s main task appeared to be to write prescriptions and 40% felt that they knew more about their epilepsy than their
GP. However, the women generally perceived that their GP or hospital specialists were sympathetic to their condition and their
concerns.
c© 1999 BEA Trading Ltd
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In 1991 the British Epilepsy Association (BEA) car-
ried out a survey of its members, looking particu-
larly at aspects of management of seizure disorders1.
The aim of this study was to see if there had been
many changes since then but also to look specifically
at issues relating to the management of women with
epilepsy. This article reports the findings with respect
to diagnosis and management of seizure disorders in
women. A previous article has reviewed women’s is-
sues2.
MATERIALS AND METHODS
A questionnaire was designed in consultation with
Taylor Nelson Sofres Health-care, an independent
market research agency. This questionnaire was sent
to 6000 BEA women members. Not all these women
would have had epilepsy—some would have been car-1059–1311/99/070398 + 06 $12.00/0ers, others friends etc. Only females with epilepsy
aged 16 or above were asked to fill in the question-
naire. This questionnaire was devised following quali-
tative research with women with epilepsy which was
also conducted by Taylor Nelson Sofres Health-care.
RESULTS
Data in the study is based on the 1855 (31%) ques-
tionnaires which were returned by the cut-off date for
inclusion in the study.
Patient demographics
The ages of the respondents are summarized in Ta-
ble 1 and their marital and domestic status in Tables 2
and 3. Eight hundred and eighty (47%) women had
had children: 292 (16%) currently had children under
the age 10.c© 1999 BEA Trading Ltd
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Table 1: Age of patients (n = 1885).
Under 16 27 1%
16–25 260 14%
26–35 497 26%
36–45 419 23%
46–55 385 21%
Over 55 265 14%
Not stated 2 < 1%
Table 2: Marital status (n = 1885).
Married/living with partner 1107 60%
Single 531 29%
Divorced/separated/widowed 184 10%
Not stated 63 3%
Table 3: Domestic situation.
Living on own 257 14%
Living with others 1568 85%
Parents/carers 318 17%
Husband/partner 717 39%
+ children 390 21%
Children 68 4%
Friends 93 5%
Table 4: Length of time since diagnosis (n = 1885).
Years n Percentage
<2 185 10%
3–5 251 13%
5–10 328 18%
11–20 459 25%
21–30 292 16%
31–40 197 11%
>40 80 4%
One thousand and ninety three (59%) of the women
were attending a hospital clinic for their epilepsy.
Table 5: Who made the diagnosis?
Hospital specialist 1580 85%
Neurologist 1091 69%
Paediatrician 191 12%
General physician 119 8%
Psychiatrist 23 1%
Neurosurgeon 8 1%
Do not know/not stated 162 10%
General practitioner 369 20%
Not stated 26 1%
Table 6: Seizure frequency and perception of severity of
seizure disorder.
Perceived severity of epilepsy
Seizure frequency Total Mild Moderate Severe
Total 1855 990 (53%) 635 (34%) 181 (10%)
Daily seizures 68 (4%) 10 25 32
Most days 87 (5%) 14 45 28
2–3/week 153 (8%) 23 88 36
1/week 149 (8%) 39 90 17
1/month 195 (11%) 77 93 21
Every 2–3 months 130 (7%) 70 54 4
Every 4–6 months 100 (5%) 46 43 9
1/year 78 (4%) 34 38 3
<1/year 105 (6%) 70 30 5
Rarely 443 (24%) 361 65 12
Seizure free 298 (16%) 222 51 6
Not stated 49 (3) 24 13 8The diagnosis of epilepsy
The majority of women were diagnosed as having
epilepsy for more than 10 years previously (55%)
whilst nearly a third (31%) were diagnosed more than
20 years previously. Twenty-three percent of respon-
dents were diagnosed within the last 5 years. The aver-
age length time since diagnosis was 16 years (Table 4).
Eighty-five percent of the women claimed that the
diagnosis of epilepsy was made by a hospital special-
ist, most commonly a neurologist (Table 5). However,
one-fifth stated that their GP made the diagnosis. This
suggests that although the GP may have made the ini-
tial diagnosis, the women were referred on to a spe-
cialist for confirmation of the diagnosis. In those cases
where a hospital specialist made the diagnosis, 69%of women were diagnosed as having epilepsy by a
neurologist, while a further 12% were diagnosed by
a paediatrician.
Seizure frequency
Forty percent of women stated that their seizures were
rare or that they were seizure free. However, 36% had
at least one seizure per month whilst 25% had one or
more seizure per week (Table 6).
Although 36% of women had a seizure at least once
a month, only 10% of these women considered their
epilepsy to be severe, while 52% felt that their epilepsy
was mild and a third considered it to be moderate.
Conversely of those women who were seizure, free
2% still considered that they had ‘severe’ epilepsy
whilst another 17% felt that they had moderately se-
vere epilepsy (Table 6).Seizure type
Many women were unclear as to the type of seizure
disorder they had or used the incorrect name (Table 7).
Eleven percent of the women were unaware of the
type of seizures they had. Over half the women (54%)
claimed that they experienced tonic–clonic or grand
mal seizures while a further 20% claimed that they
400 P. Crawford & P. Leehad ‘petit mal’ and another 10% ‘absence’ seizures.
Twenty percent mentioned experiencing complex par-
tial seizures whilst 3% stated that they had simple par-
tial seizures.Table 7: Seizure classification in 1885 women.
Seizure type n Percentage
Localization-related
Simple partial 94 5%
Complex partial 379 20%
Tonic–clonic 1024 54%
Generalized
‘absence/petit mal’ 544 29%
Myoclonic 8 0.5%
Photosensitive tonic–clonic 8 0.5%
Atonic 26 2%
Do not know/not stated 201 11%
Table 9: Length of time on the medication/combination of
medications (n = 1885).
Length of time n Percentage
< 6 months 121 7%
6–12 months 155 8%
1–2 years 192 10%
> 2 years 623 34%
Since diagnosis 605 33%
Not stated 159 9%The women were asked to describe what happened
during one of their seizures. Around half of the women
mentioned some effect on the body or convulsions,
whilst a similar proportion mentioned some loss of
consciousness. Twenty-three percent of respondents
mentioned losing consciousness for a short period of
time (1–5 minutes).
Management of epilepsy
The majority of the women (89%) stated that they
currently took older antiepileptic medications (bar-
biturates, phenytoin, carbamazepine and sodium val-
proate), either as monotherapy or in combination with
others. Newer antiepileptic drugs (vigabatrin, lamo-
trigine, gabapentin and topiramate) were prescribed to
30% of women (Table 8).Table 8: Antiepileptic drug therapy (n = 1885).
Phenobarbitone 87 5%
Phenytoin 300 16%
Carbamazapine/Tegretol SR 835 47%
Sodium valproate/Epilim retard 635 32%
Lamotrigine 341 18%
Gabapentin 111 6%
Vigabatrin 78 4%
Topiramate 77 4%
Clobazam 130 7%
Monotherapy 1102 59%In total, three-fifths of the women (59%) were cur-
rently taking monotherapy, a third of the women were
prescribed two drugs, whilst one-tenth took three or
more drugs. The majority of women prescribed newer
therapies received these in general as add-on therapy
to older antiepileptic drugs—only 6% of women pre-
scribed newer therapies took them as monotherapy.
Looking at individual therapies, 27% of the women
were prescribed carbamazapine whilst an additional20% prescribed Tegretol Retard. Sodium valproate
was taken by 25% of women and a further 7% were
prescribed Epilim Chrono.
Lamotrigine was the most frequently prescribed of
the newer antiepileptic drugs—almost one-fifth (18%)
of women were currently taking it. Women prescribed
lamotrigine were more likely to take this as monother-
apy (24%) than women prescribed one of the other
new antiepileptic drugs: gabapentin (10%), vigabatrin
(12%) or topiramate (7%).
Phenobarbitone was only taken by women who were
diagnosed more than 3 years ago. Phenytoin was less
likely to be prescribed to women diagnosed within the
last 2 years (only 7% of those diagnosed in the previ-
ous 2 years were prescribed phenytoin).
One-third of women indicated that they had not
changed their medication since diagnosis, whilst a fur-
ther third (34%) had been taking their current medica-
tion for least 3 years (Table 9).Effects of epilepsy and medication
The women respondents were asked to describe how
their seizure disorder affected them. They attributed
a wide variety of effects to their condition (Table 10).
The most frequently mentioned effects concerned cog-
nition. Over half the women mentioned a variety
of cognitive side-effects including tiredness, forget-
fulness, confusion and a lack of concentration. The
women also associated emotional and cosmetic side-
effects together with effects on the central nervous sys-
tem. Over half the women (52%) reported that they
experienced mood changes which they related to their
epilepsy. The main central nervous system side-effects
reported were poor coordination, shakiness and dizzi-
ness. The women also perceived that they had expe-
rienced weight gain or loss, hair growth or loss and
changes in their monthly cycle due to epilepsy: each
effect was mentioned by over one-third of respon-
dents.
The women were also asked which side-effects they
felt were due to their antiepileptic medication. Re-
sponses indicated that the women ascribed similar ef-
fects to both their medication and epilepsy, and indeed
a sizeable proportion of respondent were unable to dis-
tinguish an effect of their condition from a side-effect
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Table 12: Concerns about medication.from their medication. Again, the most frequently
mentioned side-effects were cognitive. Tiredness and
forgetfulness were commonly mentioned. The most
notable differences concerned cosmetic side-effects.
Weight gain due to medication was mentioned by 55%
of the total sample compared to 41% attributing it
to their epilepsy. Similarly, a greater proportion of
women considered hair loss or hair growth to be a side-
effect of their medication.Table 10: Side-effects attributed to epilepsy and medication.
Side-effect Associated with Associated with
epilepsy medication
Tiredness 61% 70%
Forgetfulness 60% 58%
Feeling confused 58% 48%
Difficulty in concentrating 57% 56%
Mood changes 52% 50%
Poor coordination 51% 47%
Shakiness 51% 46%
Dizziness 48% 44%
Sluggishness 48% 47%
Slurring words 47% 43%
Weight gain 41% 55%
Changes in monthly cycle 37% 39%
Hair loss 35% 42%
More hair growth 35% 41%
Weight loss 34% 36%
Table 11: Impact of side-effects on women’s lives.
Side-effect Mean score
Tiredness 3.3
Forgetfulness 3.1
Difficulty in concentrating 3.0
Feeling confused 2.7
Sluggishness 2.1
Slurring words 2.5
Mood changes 2.8
Poor coordination 2.5
Shakiness 2.5
Dizziness 2.3
Weight gain 2.7
Weight loss 1.4
Hair loss 1.6
Hair growth 1.7
Changes in monthly cycle 2.0
Women were asked to indicate the impact of each side-effect on the
lives, using a five-point scale (where 1 = no impact at all and 5 =
major impact).
Statement Mean score
I am concerned about the long-term effects of
my medication
4.1
I wish my medication would control my seizures
better
3.6
My medication allows me to lead a normal life 3.6
I wish I was able to change my medication to
one with fewer side-effects
3.3
I am reluctant to change my medication 3.8
My medication makes me sleep more than I
would like to
3.5
I have trouble remembering things since taking
my medication
3.5
My medication restricts my choice of
contraception
3.2
I am worried about taking the pill with my
epilepsy drugs
3.4
I am worried about taking my medication during
pregnancy
4.0
The side-effects of my medication may keep
difficult for me to look after my children
2.2
I worry about my appearance because of the
side-effects of my medication
2.9
I feel frustrated because my medication has
made me put on weight
3.5
I worry about the weight I have lost since taking
my current medication
1.8
The women were asked to indicate their level of agreement with a
series of statements concerning their medication, on a five-point
scale (where 1 = disagree strongly and 5 = agree strongly).
Table 13: Frequency of GP visits.
How often do you How often would you
see your GP? like to see your GP?
Once a month 8% 9%
2–3 months 16% 15%
4–6 months 18% 19%
Once a year 13% 19%
Less than once a year 15% 7%
Never 17% 11%In general, cognitive side-effects were considered to
have the greatest impact on the women’s lives (Ta-
ble 11). Conversely, cosmetic side-effects, apart from
weight gain, were perceived to have the least impact
on daily life. Tiredness had the greatest impact on
the women’s lives: 70% of the sample considered that
the lack of energy had least a moderate impact on
their life. This was followed by forgetfulness (61%
indicated some impact) and difficult in concentrating
(60%). Other cognitive side-effects were considered to
have a moderate impact on a woman’s life.Overall, 69% of women were concerned about the
long-term effects of their medication, but believed that
their medication allowed them to lead a normal life
(Table 12). Thirty-eight percent would have liked bet-
ter seizure control whilst 32% agreed that they would
prefer to change to a medication with fewer side-
effects. However, 49% were reluctant to change their
medication.Medical care
Women were asked about who they saw regularly
about their epilepsy and how often they saw either
their GP or their hospital specialist (Tables 13 and 14).
Fifty-nine percent stated that they saw their hospi-
tal specialist regularly whilst half the sample (49%)
saw their GP regularly. Of the hospital specialists, the
women most frequently mentioned seeing a neurolo-
gist (50% of the total sample).
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Table 14: Frequency of specialist visits.
How often How often
do you see would you like to see
your specialist? your specialist?
Once a month 1% 3%
2–3 months 10% 13%
4–6 months 23% 18%
Once a year 11% 24%
Less than once a year 11% 8%
Never 17% 10%
Not stated 27% 24%As would be expected, the women saw their GP
more often than they saw their hospital specialist.
The women consulted their GP about their epilepsy
around an average of three times a year (2.7 times),
whilst they visit the hospital specialist around twice a
year (1.8 times). Indeed while only one-third (34%)
of women saw their specialist twice a year or more,
42% consulted their GP at least twice a year. Sev-
enteen percent of women never see their GP and/or
never see a hospital specialist about their epilepsy.
On average, women had last seen their GP 5 months
previously, and longer time had elapsed since their
last consultation with their specialist (8 months pre-
viously). Women however would have liked to have
seen their GP or hospital specialist about their seizure
disorder slightly more often (3.1 times and 2.2 times
per year, respectively). Eighty-eight women (5%) with
drug resistant epilepsy (1 or more seizure/month) were
not or were rarely attending a specialist clinic.
The women were asked about the issues they dis-
cussed with their general practitioners and specialist. It
was evident from their replies that hospital specialists
on the whole, played a more active role in the manage-
ment of epilepsy than GPs. The women felt that their
GP’s main task appeared to be to write prescriptions
(mentioned by 68%). Only around one-third of women
(35%) said that they discussed seizure control or re-
ceived general lifestyle advice from their GP (31%).
Only one-quarter (25%) said that they discussed side-
effects with their GP. However, those women visit-
ing their GP more than once a year were more likely
to discuss issues surrounding seizure control (52%),
lifestyle (41%) and side-effects (37%) with their GP
than the total sample.
In contrast, 56% of the women stated that they dis-
cuss seizure control with their specialist, while 39%
mentioned side-effects had been discussed. A slightly
lower proportion (36%) said they had received gen-
eral lifestyle advice from their specialist. Again, those
women who visited their specialist more than once a
year were more likely to have discussed these issues
in comparison with the total sample.
The women generally perceived that their GP or spe-
cialists were sympathetic to their condition and to theirconcerns. The women felt that they were able to talk
to either the GP or the specialist about medication
changes, but a lower proportion (32%) felt that their
GP would change their medication if asked. Forty per-
cent of women felt that they knew more about their
epilepsy than their GP.
DISCUSSION
Although a large number of women returned the
questionnaire, they were not wholly representative of
women with epilepsy. The women respondents tended
to have had a more severe seizure disorder in that only
40% had well-controlled epilepsy. Community-based
audit studies of epilepsy suggest that at least 60%
of women with a history of epilepsy were in remis-
sion and were seizure free3, 4. Fifty-nine percent of the
women who returned the questionnaire were currently
being followed up in a hospital outpatient clinic. In a
recent general practice audit study, 48% of all patients
with epilepsy were currently being followed up in a
hospital outpatient clinic3. Overall 85% of women had
had their epilepsy diagnosed by a hospital specialist;
the majority had stated that they had seen a neurolo-
gist. This correlates well with recent general practice
audit data where 79% of people had been seen at a
hospital for their epilepsy and 48% had been seen in
the previous year3.
Despite the higher than average number of women
attending hospital outpatient clinics, some women
(5% of respondents) with frequent seizures (one or
more per month) were rarely or not being seen in
secondary or tertiary care. This may have related
to the fact that many women with frequent seizures
perceived their epilepsy to be of mild or moderate
severity.
In common with previous studies5, many women
were unsure or incorrect as to their seizure type, for
example 29% of the women claimed to have absence
or petit mal seizures. Absence seizures are uncom-
mon in adulthood, most have ceased by the time the
person reaches adulthood. Conversely, complex par-
tial and simple posture seizures, which are probably
the most common seizure type in adult life, were re-
ported by 20% and 5% respectively. Even when asked
to state what happened during their seizures, many
women were unclear—only half mentioned that they
lost consciousness.
The majority of women in this survey were re-
ceiving older antiepileptic drugs. However the use of
the newer antiepileptic agents was increasing—30%
were taking one of the four newly licensed drugs.
This may in part be due to the fact that many of the
women have continuing seizures despite antiepileptic
drug therapy and are attending hospital clinics where
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newer antiepileptic drugs. Community-based studies
suggest that between 4 and 6% of patients took one of
the newer antiepileptic drugs6. This was also reflected
in the percentage of women on monotherapy (59%)
which was lower than in a recent community-based
general practice audit study where 71% of 502 patients
were on monotherapy3.
The high number of women reporting side-effects
was even greater than in the previous BEA study.
Nearly three-quarters of women felt tired on their
medication and in many this was of a severity which
they said interfered with their lives. This would sug-
gest that there is a need for new antiepileptic drugs
with improved side-effect profiles. However, although
the majority of women stated that they would have
liked to have taken a more effective medication with
fewer side-effects, many also said that they would be
reluctant to change their therapy.
A recent study looked at the quality of care and
treatment for women with epilepsy. The side-effects
of treatment were a common cause of dissatisfaction
amongst women with epilepsy and some women felt
that these were worse than the seizures themselves7.
Most women in this study were happy with the fre-
quency with which they saw their GPs and hospital
specialists. However many women felt that their GP’s
main function was to write prescriptions! Another re-
cent study suggested that GPs should have a broader
factual knowledge of epilepsy, especially relating to
types of seizures and antiepileptic drug usage. The
same study also found that people with epilepsy pre-
ferred to have their epilepsy managed in secondary
care but was generally satisfied with the services pro-
vided by their general practitioner. The few patients
who had been referred to an epilepsy clinic felt there
had been an improvement in their epilepsy care after
referral particularly in respect of information giving8.
In our study, a third of the women felt that their GP
would change their antiepileptic medication if asked,
but a recent study looking at patients views on primary
care suggested that this was rarely done. Ninety-two
percent of people stated that their doses were rarely or
never altered and only 3% had had their antiepileptic403
drug changed by their GP8. This primary care study
suggested that overall the majority of people with
epilepsy preferred shared care between general prac-
tice and the hospital service.
In summary, the majority of women in this study
were concerned about their drug treatments, in par-
ticular the side-effects. Nearly three quarters of the
respondents felt that side-effects, especially tiredness
had a major impact on their lives. They were relatively
happy about the frequency with which they were seen
either by their GP or hospital specialist and felt that
they both were sympathetic both to their epilepsy and
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